Related Experiment Video

Updated: Jun 5, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

A practical approach to lipid management in the elderly

A Viljoen1

  • 1Department of Chemical Pathology, Lister Hospital, Stevenage, Hertfordshire SG1 4AB, UK. adie.viljoen@nhs.net

The Journal of Nutrition, Health & Aging
|January 27, 2011
PubMed

Insights

Cardiovascular disease risk significantly rises in older adults. Statin therapy shows benefits for elderly individuals, but more data is needed for those over 80 and other lipid-lowering drugs.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) incidence escalates with age, particularly after 65 years in men and 75 years in women.
  • The majority of cardiovascular events occur in individuals over 65.
  • Assessing hyperlipidemia, estimating cardiovascular risk, and managing drug safety/tolerability present unique challenges in the elderly.

Purpose of the Study:

  • To review the evidence for lipid-modifying therapies in older adults.
  • To highlight the importance of risk-benefit assessment for preventive strategies in the aging population.

Main Methods:

  • Review of clinical trial data on statin treatment in the elderly.
  • Analysis of existing literature on lipid-modifying medications in older individuals.
  • Consideration of demographic trends in life expectancy and healthcare costs.

Main Results:

  • Clinical trials confirm the benefits of statin therapy for primary and secondary CVD prevention in the elderly.
  • Limited data exists for statin use in individuals older than 80 years.
  • Data on other lipid-modifying medications in the elderly population is scarce.

Conclusions:

  • Preventive cardiovascular strategies are crucial for improving quality of life and reducing healthcare costs in aging populations.
  • Clinical decision-making must carefully weigh the risks and benefits of lipid-lowering treatments in older adults.
  • Further research is needed, especially for individuals over 80 and for non-statin lipid-modifying drugs.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...